DelveInsight’s “Bronchiolitis Obliterans Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Bronchiolitis Obliterans Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Bronchiolitis Obliterans Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Bronchiolitis Obliterans Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Bronchiolitis Obliterans Syndrome: An Overview
Bronchiolitis obliterans, also known as obliterative bronchiolitis, constrictive bronchiolitis, popcorn lung, or bronchiolitis obliterans syndrome (BOS), is an obstructive lung disease of the small airways. It usually occurs after lung transplantation or hematopoietic stem cell transplantation (HSCT).
BOS is a rare disease with characteristic features of fibrosis of terminal and distal bronchioles and spirometry showing airflow obstruction. It usually leads to a progressive decline in lung function and has variable outcomes. Bronchiolitis obliterans after HCT, also known as lung chronic graft-versus-host disease (GVHD), is an insidious disease with poor outcomes where the donor immune system attacks the small airways in the lungs, leading to obstructive pulmonary disease and air trapping.
Bronchiolitis Obliterans Syndrome Market Key Facts
-
In 2022, the total diagnosed prevalent Bronchiolitis Obliterans Syndrome (BOS) cases were approximately 32,600 in the 7MM, which is expected to grow during the study period, i.e., 2019-2032.
-
The total incident cases of lung transplant and hematopoietic stem cell transplant in the United States were approximately 2,600 and 9,600, respectively, in 2021.
-
The total market size of Bronchiolitis Obliterans Syndrome (BOS) in the United States accounted for approximately USD 31 million in 2022.
-
In EU4 and the UK, the total market size of Bronchiolitis Obliterans Syndrome (BOS) was approximately USD 24 million in 2022.
-
In Japan, the total market size of Bronchiolitis Obliterans Syndrome (BOS) was approximately USD 2 million in 2022.
Bronchiolitis Obliterans Syndrome Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Bronchiolitis Obliterans Syndrome pipeline therapies. It also thoroughly assesses the Bronchiolitis Obliterans Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Bronchiolitis Obliterans Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Bronchiolitis Obliterans Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Bronchiolitis Obliterans Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Bronchiolitis Obliterans Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Bronchiolitis Obliterans Syndrome Epidemiology, Segmented as –
-
Incident Cases of Lung Transplant in the 7MM [2019-2032]
-
Diagnosed Prevalence of BOS after Lung Transplant in the 7MM [2019-2032]
-
Incident Cases of Hematopoietic Stem Cell Transplant in the 7MM [2019-2032]
-
Diagnosed Prevalence of BOS After Hematopoietic Stem Cell Transplants in the 7MM [2019-2032]
-
Grade-wise BOS Cases in the 7MM [2019-2032]
Bronchiolitis Obliterans Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Bronchiolitis Obliterans Syndrome market or expected to be launched during the study period. The analysis covers the Bronchiolitis Obliterans Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Bronchiolitis Obliterans Syndrome drugs based on their sale and market share.
The report also covers the Bronchiolitis Obliterans Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Bronchiolitis Obliterans Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Bronchiolitis Obliterans Syndrome Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market
Bronchiolitis Obliterans Syndrome Therapeutics Analysis
Currently, there is no approved therapy in the 7MM to treat Bronchiolitis Obliterans Syndrome (BOS), and some potential therapeutic options are being investigated in the late stages of the disease and have the potential to change the market scenario and treatment dynamics of Bronchiolitis Obliterans Syndrome (BOS) in the coming years.
On March 30, 2023, Renovion, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARINA-1 for the prevention of bronchiolitis obliterans syndrome (BOS) progression in adults with a bilateral lung transplant.
Several major pharma and biotech giants are developing therapies for Bronchiolitis Obliterans Syndrome. Currently, Zambon is leading the therapeutics market with its Bronchiolitis Obliterans Syndrome drug candidates in the most advanced stage of clinical development.
Bronchiolitis Obliterans Syndrome Companies Actively Working in the Therapeutics Market Include
-
Zambon SpA
-
Pirfenidone
-
Zambon Pharma
-
GlaxoSmithKline
-
Incyte Corporation
-
Mereo Biopharma
-
Genentech
And many others
Emerging and Marketed Bronchiolitis Obliterans Syndrome Therapies Covered in the Report Include:
-
ALTA 2530: Altavant Sciences
-
Alvelestat: Mereo BioPharma
-
Itacitinib: Incyte Corporation
-
KT-1002: Koutif Therapeutics
-
Liposomal Cyclosporine A: Zambon SpA
-
MPH966 (alvelestat): Mereo Biopharma
-
Pirfenidone: Genentech
-
Ruxolitinib: Incyte Corporation
And many more
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Bronchiolitis Obliterans Syndrome Competitive Intelligence Analysis
4. Bronchiolitis Obliterans Syndrome Market Overview at a Glance
5. Bronchiolitis Obliterans Syndrome Disease Background and Overview
6. Bronchiolitis Obliterans Syndrome Patient Journey
7. Bronchiolitis Obliterans Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Bronchiolitis Obliterans Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Bronchiolitis Obliterans Syndrome Unmet Needs
10. Key Endpoints of Bronchiolitis Obliterans Syndrome Treatment
11. Bronchiolitis Obliterans Syndrome Marketed Therapies
12. Bronchiolitis Obliterans Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Bronchiolitis Obliterans Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Bronchiolitis Obliterans Syndrome Market Outlook (In US, EU5, and Japan)
16. Bronchiolitis Obliterans Syndrome Companies Active in the Market
17. Bronchiolitis Obliterans Syndrome Access and Reimbursement Overview
18. KOL Views on the Bronchiolitis Obliterans Syndrome Market
19. Bronchiolitis Obliterans Syndrome Market Drivers
20. Bronchiolitis Obliterans Syndrome Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Homocystinuria Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Homocystinuria market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Homocystinuria market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices